These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21385075)

  • 1. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
    Toubert ME; Vercellino L; Faugeron I; Lussato D; Hindie E; Bousquet G
    Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
    Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib: muscle wasting.
    Prescrire Int; 2011 Dec; 20(122):296-7. PubMed ID: 22216546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
    Pérez López G; Carrasco De La Fuente M; Menacho Román M; González Albarrán O; Cano Megías M
    Endocrinol Nutr; 2011 Feb; 58(2):94-6. PubMed ID: 21333617
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
    Higuchi Y; Motoki T; Ishida H; Kanamitsu K; Washio K; Oyama T; Noda T; Tsurumaru Y; Okada A; Tsukahara H; Shimada A
    BMC Cancer; 2017 Nov; 17(1):775. PubMed ID: 29162036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.
    Pantaleo MA; Mandrioli A; Saponara M; Nannini M; Erente G; Lolli C; Biasco G
    BMC Cancer; 2012 Jun; 12():231. PubMed ID: 22687270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with sorafenib in advanced thyroid cancer - a case report.
    Krajewska J; Olczyk T; Roskosz J; Paliczk-Cieślik E; Smietana AK; Kaczmarek-Borowska B; Jarząb B
    Endokrynol Pol; 2010; 61(5):492-6. PubMed ID: 21049464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
    Crespo O; Kang SC; Daneman R; Lindstrom TM; Ho PP; Sobel RA; Steinman L; Robinson WH
    J Clin Immunol; 2011 Dec; 31(6):1010-20. PubMed ID: 21847523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
    Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
    Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Schmidinger M; Zielinski CC; Vogl UM; Bojic A; Bojic M; Schukro C; Ruhsam M; Hejna M; Schmidinger H
    J Clin Oncol; 2008 Nov; 26(32):5204-12. PubMed ID: 18838713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
    Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
    Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
    Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
    Will Y; Dykens JA; Nadanaciva S; Hirakawa B; Jamieson J; Marroquin LD; Hynes J; Patyna S; Jessen BA
    Toxicol Sci; 2008 Nov; 106(1):153-61. PubMed ID: 18664550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors and solid tumours: case report and review of the literature.
    Roszkiewicz F; Garidi R; Vaida I; Royer B; Parcelier A; Marolleau JP; Damaj G
    Pharmacology; 2009; 84(1):38-41. PubMed ID: 19546604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
    Kimura T; Suetomi T; Miyagawa T; Tsutsumi M
    Hinyokika Kiyo; 2012 Aug; 58(8):443-6. PubMed ID: 23052271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
    Huang WS; Yang CH
    World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.